ClinicalTrials.gg
CompletedNCT01818752CLARIONUpdated Aug 26, 2019Results posted

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

A Phase 3 interventional study of Carfilzomib and Bortezomib in Multiple Myeloma, sponsored by Amgen. Completed at 213 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-26.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
955
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
Largest of 113
955 · median 54
Started
2013
with 13 others
Phase 3
15 of 113
1 open now
Registered
33rd of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one has the largest enrollment, is one of 14 that started in 2013, is one of 15 in phase 3, and was the 33rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade® (bortezomib), melphalan and prednisone (VMP).

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Newly diagnosed symptomatic multiple myeloma (per International Myeloma Working Group [IMWG] diagnostic criteria)
  2. Transplant ineligibility
  3. , as defined by 1 or more of the following (assessed within 21 days prior to randomization):

    • Serum M-protein ≥ 0.5 g/dL, or
    • Urine M-protein ≥ 200 mg/24 hours, or
    • In subjects without detectable serum or urine M-protein, serum free light chain (SFLC) > 100 mg/L (involved light chain) and an abnormal kappa lambda ratio (SFLC kappa lambda ratio \< 0.26 or > 1.65)
  4. No prior treatment for multiple myeloma
  5. (ECOG) performance status 0-2

Exclusion criteria

Exclusion Criteria:

  1. Multiple myeloma of IgM (immunoglobulin M) subtype
  2. therapy within 14 days prior to randomization that equals or exceeds a cumulative dose of 160 mg of dexamethasone
  3. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  4. Plasma cell leukemia (> 2.0 × 10\^9/L circulating plasma cells by standard differential)
  5. Waldenström macroglobulinemia (WM)
  6. Known amyloidosis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
955 participants (actual)

Study arms

  • Experimental
    Carfilzomib, Melphalan, Prednisone

    Participants received carfilzomib administered in combination with melphalan and prednisone for nine 42-day cycles. Carfilzomib was administered as an intravenous (IV) infusion on days 1, 2, 8, 9, 22, 23, 29, and 30 of each 42-day cycle. The carfilzomib dose was at 20 mg/m² on cycle 1, days 1 and 2 followed by 36 mg/m² thereafter. On days 1 to 4, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².

    Drug: Carfilzomib · Drug: Melphalan · Drug: Prednisone

  • Active comparator
    Bortezomib, Melphalan, Prednisone

    Participants received bortezomib in combination with melphalan and prednisone for nine 42-day cycles. Bortezomib was administered either IV or subcutaneously at 1.3 mg/m² during cycles 1 to 4 on days 1, 4, 8, 11, 22, 25, 29, and 32 followed by 1.3 mg/m² during cycles 5 to 9 on days 1, 8, 22, and 29. On days 1 to 4 of each cycle, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².

    Drug: Bortezomib · Drug: Melphalan · Drug: Prednisone

Interventions

  • Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.

    Also known as: Krypolis®

  • Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.

    Also known as: Velcade®

  • Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.

  • Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Progression-free survival was defined as the time from randomization to the earlier of documented disease progression or death due to any cause. PFS was analyzed using Kaplan-Meier methods. The duration of PFS was censored for participants with no baseline and/or post-baseline disease assessments, who started a new anti-cancer therapy before documentation of disease progression or death, death or disease progression after missed disease assessment of 100 consecutive days or longer, or who were alive without documentation of disease progression before the data cutoff date, including lost to follow-up prior to disease progression. Participants were evaluated for disease response and progression according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC), determined centrally using a validated computer algorithm in a blinded manner.

    Time frame: From randomization until the data cut-off date of 15 July 2016; median follow-up time for PFS was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival (OS) was defined as the time from randomization to the date of death (whatever the cause). Participants who were alive or lost to follow-up as of the data analysis cut-off date were censored on the date the patient was last known to be alive. Median overall survival was estimated using the Kaplan-Meier method.

    Time frame: From randomization until the data cut-off date of 15 July 2016; median follow-up time for OS was 22.2 and 22.5 months in the bortezomib and carfilzomib arms respectively.

  2. Overall Response Rate

    Disease response was evaluated according to the IMWG-URC using a validated computer algorithm. Overall response was defined as the percentage of participants with a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM biopsy; VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-protein with urine M-protein \<100 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. PR: ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline.

    Time frame: Disease response was assessed every 3 weeks during the first 54 weeks and every 6 weeks thereafter until PD or the data cut-off date of 15 July 2016; median follow-up time was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.

  3. Complete Response Rate

    Complete response rate was defined as the percentage of participants in each treatment group who achieved a sCR or CR per the IMWG-URC as their best response. sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM biopsy.

    Time frame: Disease response was assessed every 3 weeks during the first 54 weeks and every 6 weeks thereafter until PD or the data cut-off date of 15 July 2016; median follow-up time was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.

  4. Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy

    Neuropathy events were defined as Grade 2 or higher peripheral neuropathy as specified by peripheral neuropathy Standardised Medical Dictionary for Regulatory Activities (MedDRA) Query, narrow (scope) (SMQN) terms. Peripheral neuropathy was assessed by neurologic exam and graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03: Grade 1: Asymptomatic; Grade 2: Moderate symptoms, limiting instrumental activities of daily living (ADL) Grade 3: Severe symptoms; limiting self-care ADL; Grade 4: Life-threatening consequences, urgent intervention indicated; Grade 5: Death.

    Time frame: From the first dose of any study drug up to 30 days after the last dose of any study drug as of the data cut-off date of 15 July 2016; median duration of treatment was 52 weeks in both treatment groups.

  5. European Organisation for Research and Treatment of Cancer Quality of Life Core Module (EORTC QLQ-C30) Global Health Status/Quality of Life (QOL) Scores

    The EORTC QLQ-C30 is a validated self-rating questionnaire including 30 items used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale was scored between 0 and 100, with higher scores indicating better Global Health Status/QOL.

    Time frame: Baseline, weeks 6, 12, 18, 24, 30, 36, 42 and 48

  6. Number of Participants With Adverse Events

    Adverse events (AEs)were graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03, where GRADE 1 = Mild; GRADE 2 = Moderate; GRADE 3 = Severe; GRADE 4 = Life-threatening; GRADE 5 = Fatal. A serious adverse event is an adverse event that met 1 or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * Congenital anomaly/birth defect * Important medical event that jeopardized the participant and may have required medical or surgical intervention to prevent 1 of the outcomes listed above. Treatment-related adverse events are adverse events considered related to at least 1 investigational product by the investigator, including those with unknown relationship.

    Time frame: From the first dose of any study drug up to 30 days after the last dose of any study drug as of the data cut-off date of 15 July 2016; median duration of treatment was 52 weeks in both treatment groups.

07

Results

Posted Aug 1, 2017

Participant flow

This study was conducted at 183 centers in Argentina, Australia, Austria, Belgium, Bulgaria, Canada, China, Czech Republic, France, Germany, Greece, Hungary, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Poland, Romania, Russia, Singapore, South Korea, Spain, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, and United States.

Participant flow — Overall Study
MilestoneBortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, Prednisone
Started477478
Received treatment470474
Completed290280
Not completed187198
Withdrew: Adverse event6474
Withdrew: Death1418
Withdrew: Non-compliance1620
Withdrew: Withdrawal by subject1514
Withdrew: Physician decision98
Withdrew: Disease progression5448
Withdrew: Other78
Withdrew: Continuing treatment14
Withdrew: Randomized but not dosed74

Outcome measures

PrimaryProgression-Free Survival (PFS)

Progression-free survival was defined as the time from randomization to the earlier of documented disease progression or death due to any cause. PFS was analyzed using Kaplan-Meier methods. The duration of PFS was censored for participants with no baseline and/or post-baseline disease assessments, who started a new anti-cancer therapy before documentation of disease progression or death, death or disease progression after missed disease assessment of 100 consecutive days or longer, or who were alive without documentation of disease progression before the data cutoff date, including lost to follow-up prior to disease progression. Participants were evaluated for disease response and progression according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC), determined centrally using a validated computer algorithm in a blinded manner.

Time frame:
From randomization until the data cut-off date of 15 July 2016; median follow-up time for PFS was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsBortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, Prednisone
Progression-Free Survival (PFS)22.1 (20.8 to 24.4)22.3 (20.9 to 26.7)
Statistical analysis
  • Bortezomib, Melphalan, Prednisone vs Carfilzomib, Melphalan, Prednisone · Log Rank · p = 0.1590 (The p-value boundary for PFS analysis was 0.02141.) · Hazard ratio (hr): 0.906 · 95% CI 0.746 to 1.101The hazard ratio (Carfilzomib/Bortezomib) was estimated using a Cox proportional hazards model stratified by ISS stage, choice of route of bortezomib administration, region and age.
SecondaryOverall Survival (OS)

Overall survival (OS) was defined as the time from randomization to the date of death (whatever the cause). Participants who were alive or lost to follow-up as of the data analysis cut-off date were censored on the date the patient was last known to be alive. Median overall survival was estimated using the Kaplan-Meier method.

Time frame:
From randomization until the data cut-off date of 15 July 2016; median follow-up time for OS was 22.2 and 22.5 months in the bortezomib and carfilzomib arms respectively.
Reported as:
Median · months
Overall Survival (OS)
monthsBortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, Prednisone
Overall Survival (OS)NA (NA to NA)NA (31.5 to NA)
Statistical analysis
  • Bortezomib, Melphalan, Prednisone vs Carfilzomib, Melphalan, Prednisone · Log Rank · p = 0.8934 (Based on the pre-specified multiplicity adjustment method, secondary endpoints were to be tested only if the results of the primary endpoint were significant. The p-values for all secondary endpoints are descriptive only.) · Hazard ratio (hr): 1.211 · 95% CI 0.896 to 1.637The hazard ratio (Carfilzomib/Bortezomib) was estimated using a Cox proportional hazards model stratified by ISS stage, choice of route of bortezomib administration, region and age.
SecondaryOverall Response Rate

Disease response was evaluated according to the IMWG-URC using a validated computer algorithm. Overall response was defined as the percentage of participants with a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM biopsy; VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-protein with urine M-protein \<100 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. PR: ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline.

Time frame:
Disease response was assessed every 3 weeks during the first 54 weeks and every 6 weeks thereafter until PD or the data cut-off date of 15 July 2016; median follow-up time was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsBortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, Prednisone
Overall Response Rate78.8 (74.9 to 82.4)84.3 (80.7 to 87.5)
Statistical analysis
  • Bortezomib, Melphalan, Prednisone vs Carfilzomib, Melphalan, Prednisone · Stratified Cochran-Mantel-Haenszel · p = 0.0218 (Based on the pre-specified multiplicity adjustment method, secondary endpoints were to be tested only if the results of the primary endpoint were significant. The p-values for all secondary endpoints are descriptive only.) · Odds ratio (or): 1.412 · 95% CI 1.010 to 1.973Odds ratio (Carfilzomib/Bortezomib) was estimated using the Mantel-Haenszel method stratified by ISS stage, choice of route of bortezomib administration, region and age.
SecondaryComplete Response Rate

Complete response rate was defined as the percentage of participants in each treatment group who achieved a sCR or CR per the IMWG-URC as their best response. sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM biopsy.

Time frame:
Disease response was assessed every 3 weeks during the first 54 weeks and every 6 weeks thereafter until PD or the data cut-off date of 15 July 2016; median follow-up time was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.
Reported as:
Number · percentage of participants
Complete Response Rate
percentage of participantsBortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, Prednisone
Complete Response Rate23.1 (19.4 to 27.1)25.9 (22.1 to 30.1)
Statistical analysis
  • Bortezomib, Melphalan, Prednisone vs Carfilzomib, Melphalan, Prednisone · Stratified Cochran-Mantel-Haenszel · p = 0.1388 (Based on the pre-specified multiplicity adjustment method, secondary endpoints were to be tested only if the results of the primary endpoint were significant. The p-values for all secondary endpoints are descriptive only.) · Odds ratio (or): 1.179 · 95% CI 0.875 to 1.589Odds ratio (Carfilzomib/Bortezomib) was estimated using the Mantel-Haenszel method stratified by ISS stage, choice of route of bortezomib administration, region and age.
SecondaryPercentage of Participants With ≥ Grade 2 Peripheral Neuropathy

Neuropathy events were defined as Grade 2 or higher peripheral neuropathy as specified by peripheral neuropathy Standardised Medical Dictionary for Regulatory Activities (MedDRA) Query, narrow (scope) (SMQN) terms. Peripheral neuropathy was assessed by neurologic exam and graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03: Grade 1: Asymptomatic; Grade 2: Moderate symptoms, limiting instrumental activities of daily living (ADL) Grade 3: Severe symptoms; limiting self-care ADL; Grade 4: Life-threatening consequences, urgent intervention indicated; Grade 5: Death.

Time frame:
From the first dose of any study drug up to 30 days after the last dose of any study drug as of the data cut-off date of 15 July 2016; median duration of treatment was 52 weeks in both treatment groups.
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy
percentage of participantsBortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, Prednisone
Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy35.1 (30.8 to 39.6)2.5 (1.3 to 4.4)
Statistical analysis
  • Bortezomib, Melphalan, Prednisone vs Carfilzomib, Melphalan, Prednisone · Pearson Chi-Square test · p = < 0.0001 (Based on the pre-specified multiplicity adjustment method, secondary endpoints were to be tested only if the results of the primary endpoint were significant. The p-values for all secondary endpoints are descriptive only.) · Odds ratio (or): 0.048 · 95% CI 0.026 to 0.088Unstratified odds ratio (Carfilzomib/Bortezomib) was estimated.
SecondaryEuropean Organisation for Research and Treatment of Cancer Quality of Life Core Module (EORTC QLQ-C30) Global Health Status/Quality of Life (QOL) Scores

The EORTC QLQ-C30 is a validated self-rating questionnaire including 30 items used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale was scored between 0 and 100, with higher scores indicating better Global Health Status/QOL.

Time frame:
Baseline, weeks 6, 12, 18, 24, 30, 36, 42 and 48
Reported as:
Mean · units on a scale
European Organisation for Research and Treatment of Cancer Quality of Life Core Module (EORTC QLQ-C30) Global Health Status/Quality of Life (QOL) Scores
units on a scaleBortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, Prednisone
Baseline (n = 425, 425)53.3 ± 21.953.9 ± 22.5
Week 6 (n = 412, 407)56.2 ± 19.561.1 ± 19.6
Week 12 (n = 376, 389)55.3 ± 19.862.4 ± 17.7
Week 18 (n = 341, 369)55.7 ± 18.863.2 ± 17.4
Week 24 (n = 320, 345)57.3 ± 17.663.3 ± 17.1
Week 30 (n = 298, 317)61.6 ± 17.863.0 ± 17.8
Week 36 (n = 285, 308)61.9 ± 17.564.0 ± 18.1
Week 42 (n = 275, 288)63.3 ± 17.765.0 ± 18.1
Week 48 (n = 261, 265)62.9 ± 18.465.1 ± 17.1
Statistical analysis
  • Bortezomib, Melphalan, Prednisone vs Carfilzomib, Melphalan, Prednisone · Mixed Effects Model for Repeated Measure · p = < 0.0001 (Based on the pre-specified multiplicity adjustment method, secondary endpoints were to be tested only if the results of the primary endpoint were significant. The p-values for all secondary endpoints are descriptive only.) · Least squares mean difference: 4.99 · 95% CI 3.48 to 6.51
SecondaryNumber of Participants With Adverse Events

Adverse events (AEs)were graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03, where GRADE 1 = Mild; GRADE 2 = Moderate; GRADE 3 = Severe; GRADE 4 = Life-threatening; GRADE 5 = Fatal. A serious adverse event is an adverse event that met 1 or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * Congenital anomaly/birth defect * Important medical event that jeopardized the participant and may have required medical or surgical intervention to prevent 1 of the outcomes listed above. Treatment-related adverse events are adverse events considered related to at least 1 investigational product by the investigator, including those with unknown relationship.

Time frame:
From the first dose of any study drug up to 30 days after the last dose of any study drug as of the data cut-off date of 15 July 2016; median duration of treatment was 52 weeks in both treatment groups.
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsBortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, Prednisone
All adverse events454460
AEs ≥ grade 3358354
Serious adverse events198235
Leading to discontinuation of study drug7383
Fatal adverse events2031
Treatment-related adverse events (TRAEs)431408
TRAEs ≥ grade 3285268
Treatment-related serious adverse events102136
TRAE leading to discontinuation of study drug5154
Treatment-related fatal adverse events510

Adverse events

Collected over From the first dose of any study drug up to 30 days after the last dose of any study drug as of the data cut-off date of 15 July 2016; median duration of treatment was 52 weeks in both treatment groups.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bortezomib, Melphalan, Prednisone—198/470 (42.1%)437/470 (93%)
Carfilzomib, Melphalan, Prednisone—235/474 (49.6%)437/474 (92.2%)
Most frequent serious events
Showing 10 of 292
Most frequent serious events
EventBortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, Prednisone
PneumoniaInfections and infestations31/47046/474
Cardiac failureCardiac disorders7/47021/474
Acute kidney injuryRenal and urinary disorders10/47019/474
PyrexiaGeneral disorders9/47016/474
Renal failureRenal and urinary disorders3/47014/474
ThrombocytopeniaBlood and lymphatic system disorders11/4705/474
AnaemiaBlood and lymphatic system disorders6/47011/474
DyspnoeaRespiratory, thoracic and mediastinal disorders3/4709/474
Cardiac failure congestiveCardiac disorders0/4708/474
BronchitisInfections and infestations3/4708/474
Most frequent other events
Showing 10 of 53
Most frequent other events
EventBortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, Prednisone
AnaemiaBlood and lymphatic system disorders143/470168/474
PyrexiaGeneral disorders80/470168/474
NauseaGastrointestinal disorders132/470167/474
Neuropathy peripheralNervous system disorders154/47029/474
DiarrhoeaGastrointestinal disorders132/47095/474
NeutropeniaBlood and lymphatic system disorders121/470121/474
VomitingGastrointestinal disorders88/470116/474
ConstipationGastrointestinal disorders114/47065/474
HypertensionVascular disorders32/470102/474
ThrombocytopeniaBlood and lymphatic system disorders91/47084/474

Baseline characteristics

Age, Continuous
Age, Continuous(years)Bortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, PrednisoneTotal
Mean71.5 ± 6.572.0 ± 5.771.7 ± 6.1
Sex: Female, Male
Sex: Female, Male(Participants)Bortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, PrednisoneTotal
Female238235473
Male239243482
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, PrednisoneTotal
Hispanic or Latino151833
Not Hispanic or Latino443427870
Unknown or Not Reported193352
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Bortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, PrednisoneTotal
American Indian or Alaska Native213
Asian121123244
Black or African American033
White339329668
Other314
Multiple022
Not Reported121931
Stratification Factor: International Staging System (ISS) Stage
Stratification Factor: International Staging System (ISS) Stage(participants)Bortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, PrednisoneTotal
Stage I9995194
Stage II or III378383761
Stratification Factor: Route of Bortezomib Administration
Stratification Factor: Route of Bortezomib Administration(participants)Bortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, PrednisoneTotal
Intravenous123123246
Subcutaneous354355709
Stratification Factor: Region of Enrollment
Stratification Factor: Region of Enrollment(participants)Bortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, PrednisoneTotal
Asia Pacific141140281
North America12820
Europe317320637
Other71017
Stratification Factor: Age
Stratification Factor: Age(participants)Bortezomib, Melphalan, PrednisoneCarfilzomib, Melphalan, PrednisoneTotal
< 75 years329327656
≥ 75 years148151299

1 further baseline measures are reported on the registry.

08

Study locations

213 sites
  • California Cancer Associates for Research & Excellence, Inc. (cCARE)
    Fresno, California 93720, United States
  • Marin Cancer Care
    Greenbrae, California 94904, United States
  • Sutter Gould Medical Foundation
    Modesto, California 95357, United States
  • Innovative Clinical Research Institute
    Whittier, California 90603, United States
  • UF Health Shands Cancer Hospital
    Gainesville, Florida, United States
  • Evanston KelIogg Cancer Center
    Evanston, Illinois, United States
  • Billings Clinic Cancer Center
    Billings, Montana 59101, United States
  • Maimonides Cancer Center
    Brooklyn, New York, United States
  • Weill Cornell Medical Center
    New York, New York 10021, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • Saint Francis Health System
    Greenville, South Carolina 29601, United States
  • Spartanburg Regional Healthcare System
    Spartanburg, South Carolina 29303, United States
  • Santee Hematology Oncology
    Sumter, South Carolina 29150, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington, United States
  • Centro de educacion medica c investigacioncs clinicas "Norberto Quimo' (CEMIC)
    Buenos Aires, Argentina
  • Sanatorio Britanico S.A.
    Santa Fe, Argentina
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • St. Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
  • Central Coast Local Health District
    North Gosford, New South Wales 2250, Australia
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Eastern Health - Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • St. Vincent's Hospital Melbourne
    Fitzroy, Victoria, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Border Medical Oncology
    Wodonga, Victoria 3690, Australia
  • Royal North Shore Hospital, Haematology Department
    New South Wales, Australia
  • Medical University of Innsbruck, University Clinic for Internal Medicine V
    Innsbruck, 6020, Austria
  • Elisabeth Linz Hospital
    Linz, 4020, Austria
  • Vienna Wilhelminen Hospital
    Vienna, 1160, Austria
  • ZNA, Stuivenberg
    Antwerp, Antwerpen 2060, Belgium
  • Saint Joseph Clinic Arlon, Department of Hematology
    Arlon, Luxembourg 6700, Belgium
  • CHR de La Citadelle (ENG: Citadelle Regional Hospital Center)
    Liège, 4000, Belgium
  • CHU Mont-Godinne
    Yvoir, 5530, Belgium
  • University Multiprofile Hospital for Active Treatment "Sveti Georgi", Plovdiv, Hematology Clinic
    Plovdiv, 4002, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Sveti Georgi", Plovdiv, Oncology and Hematology Clinic
    Plovdiv, 4002, Bulgaria
  • Military Medical Academy - Multiprofile Hospital for Active Treatment, Sofia, Hematology and Oncology Clinic
    Sofia, 1606, Bulgaria
  • Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Hematology Clinic
    Sofia, 1756, Bulgaria
  • Multiprofile Hospital for Active Treatment "Sveta Marina", Varna
    Varna, 9010, Bulgaria
  • CSSS-Champlain-Charles LeMoyne
    Greenfield Park, Quebec, Canada
  • Fujian Medical University Union Hospital
    Fuzhou City, Fujian, China
  • Guangdong General Hospital
    Guangzhou, Guangdong, China
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
  • The First Hospital of Jilin University
    Changchun, Jilin, China
  • The First Affiliated Hospital of the Fourth Military Medical University of PLA
    Xi'an City, Shanxi, China
  • The First Affiliated Hospital of College of Medicine, Zhejiang University - Dr. Jie Jin
    Hangzhou, Zhejiang, China
  • The First Affiliated Hospital of College of Medicine, Zhejiang University
    Hangzhou, Zhejiang, China
  • 307 Hospital of PLA
    Beijing, China
  • Beijing Chao Yang Hospital, Capital Medical University
    Beijing, China
  • Peking Union Medical College Hospital
    Beijing, China
  • Peking University Third Hospital
    Beijing, China
  • Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, China
  • Shanghai Changzheng Hospital
    Shanghai, China
  • Institute on Hematology & Blood Diseases Hospital Chinese Academy of Medical Scicnces & Peking Union Medical University
    Tianjin, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, China
  • University Hospital Brno, Department of Internal Hematology and Oncology
    Brno, 625 00, Czechia
  • University Hospital Brno, Hospital Pharmacy - Department of Dilution of Cytostasis
    Brno, 625 00, Czechia
  • University Hospital Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • University Hospital Olomouc, 3rd Clinic of Internal Medicine, Nephrology, Rheumatology and Endocrinology
    Olomouc, 775 20, Czechia
  • University Hospital Ostrava, Clinic of Hematooncology of UHO and MFUO
    Ostrava, 708 52, Czechia
  • University Hospital Kralovske Vinohrady - Internal Hematology Clinic
    Prague, 10034, Czechia
  • General University Hospital Prague, 1st Department of Medicine - Department of Hematology
    Prague, 128 08, Czechia
  • CHU de Caen, Côte de Nacre
    Caen Cedex 9, 14033, France
  • CHU Estaing
    Clermont-Ferrand, 63000, France
  • UHC Dijon, Children's Hospital
    Dijon, France
  • CHRU Hopital Huriez, Departement of Hematology
    Lille Cedex, France
  • CHRU Lille Hôpital Claude Huriez
    Lille, 59037, France
  • Paoli Calmettes Institute, Department ofHematology 2
    Marseille cedex, France
  • Nantes University Hospital Center
    Nantes Cedex 1, 44093, France
  • Centre Hospitalier Regional Universitaire de Nimes, Groupe Hospitalo-Universitaire Caremeau
    Nimes cedex 9, France
  • Hopital Saini Louis, Service d'immuno-Hematologie
    Paris, France
  • Hopital Saint Antoine
    Paris, France
  • Hospital Necker
    Paris, France
  • South Lyon Hospital Center
    Pierre Bénite, cedex, 69310, France
  • Centre Hospitalier Lyon Sud, Service d'hématologie Clinique
    Pierre Bénite, Cedex, 69495, France
  • Hopital Pontchaillou
    Rennes Cedex 9, France
  • Hospital Purpan
    Toulouse Cedex 9, France
  • CHU de Tours Hopital Bretonneau
    Tours Cedex 1, France
  • Freiburg University Medical Center
    Freiburg, Baden-Wuerttemberg, Germany
  • Ulm University Hospital, Center for Internal Medicine, Clinic of Internal Medicine III
    Ulm, Baden-Wuerttemberg, Germany
  • Ludwig Maximilians University Hospital - Medical Clinic III
    Munich, Bavaria, Germany
  • University Hospital Cologne
    Cologne, Nordrhein-Westfalen 50937, Germany
  • Johannes Gutenberg-University Mainz, Medical Clinic and Policlinic III
    Mainz, Rhineland-Palatinate, Germany
  • Saarland University Hospital
    Homburg / Saar, Saarland, Germany
  • Group Practice for Hematology and Oncology
    Dresden, 1307, Germany
  • Stiftungsklinikum Mittelrhein GmbH, Clinic of Internal Medicine
    Koblenz, 56068, Germany
  • Evangelismos Hospital
    Athens, Attica 10676, Greece
  • University of Athens, Alexandra Hospital
    Athens, 11528, Greece
  • St. Istvan and St. Laszlo Hospital of Budapest, Department of Haematology and Stem-cell Transplant
    Budapest, 1097, Hungary
  • National Institute of Oncology, Department of Oncology, Internal Medicine "A" and Hematology
    Budapest, 1122, Hungary
  • University of Debrecen, Medical and Health Science Center, Institute for Medicine, Chair of Hematology
    Debrecen, 4032, Hungary
  • Bekes County Pandy Kalman Hospital 1st Department of Internal Medicine, Hematology
    Gyula, 5700, Hungary
  • Kaposi Mor County Teaching Hospital, 2nd Department of Internal Medicine, Hematology
    Kaposvar, 7400, Hungary
  • Bacs-Kiskun County Teaching Hospital, II. Department of Internal Medicine
    Kecskemet, 6000, Hungary
  • Medical Center of the University of Pecs, 1st Clinic for Internal Medicine
    Pecs, 7624, Hungary
  • Soroka University Medical Center
    Beer-Sheva, P.O.B 151, Israel
  • Rambam Medical Center, Department of Hematology
    Haifa, 31096, Israel
  • Ein Kerem Hospital, Department of Hematology
    Jerusalem, 91120, Israel
  • The Chaim Sheba Medical Center
    Tel Hashomer, Israel
  • UO Clinica Ematologica, IRCCS A.O.U. San Martino
    Genova, GE, Italy

Showing the first 100 of 213 sites across 30 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, Hajek R, Groarke J, Lyon AR, Batty GN, Ro S, Huang M, Iskander KS, Lenihan D. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Adv. 2018 Jul 10;2(13):1633-1644. doi: 10.1182/bloodadvances.2017015545. PubMed 29991494 ↗
  • Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, Pour L, Jurczyszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019 May 2;133(18):1953-1963. doi: 10.1182/blood-2018-09-874396. Epub 2019 Feb 28. PubMed 30819926 ↗
  • Rosenthal A, Luthi J, Belohlavek M, Kortum KM, Mookadam F, Mayo A, Fonseca R, Bergsagel PL, Reeder CB, Mikhael JR, Stewart AK. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016 Jan 15;6(1):e384. doi: 10.1038/bcj.2015.112. PubMed 26771810 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in Jul 2016, 36 months.

Results were first posted in Aug 2017, 1 year after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 36 months is below that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2013
First posted
Mar 26, 2013
StartActual
Jul 8, 2013
Primary completionActual
Jul 15, 2016
CompletionActual
Nov 4, 2016
Results first posted
Aug 1, 2017
Last update
Aug 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01818752
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 26, 2013
Start date
Jul 8, 2013
Primary completion
Jul 15, 2016
Completion
Nov 4, 2016
Results posted
Aug 1, 2017
Last update
Aug 26, 2019

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carfilzomib

Start the discussion